NSEDCP
VERV

NJ State Employees Deferred Compensation Plan’s Verve Therapeutics VERV Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,000
Closed -$157K – 447
2025
Q2 		$157K Hold
14,000
– – 0.02% 410
2025
Q1 		$64K Hold
14,000
– – 0.01% 434
2024
Q4 		$79K Hold
14,000
– – 0.01% 448
2024
Q3 		$67.8K Hold
14,000
– – 0.01% 462
2024
Q2 		$68.3K Hold
14,000
– – 0.01% 457
2024
Q1 		$186K Hold
14,000
– – 0.02% 441
2023
Q4 		$195K Hold
14,000
– – 0.03% 439
2023
Q3 		$186K Hold
14,000
– – 0.03% 435
2023
Q2 		$263K Hold
14,000
– – 0.04% 395
2023
Q1 		$202K Hold
14,000
– – 0.03% 436
2022
Q4 		$271K Hold
14,000
– – 0.04% 379
2022
Q3 		$481K Buy
+14,000
New +$447K 0.08% 252

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's VERV Position: Q3 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 14,000 shares — an estimated $157K sold.

NJ State Employees Deferred Compensation Plan first reported a position in VERV in Q3 2022 and held it in 12 quarters. The position peaked at $481K in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • NJ State Employees Deferred Compensation Plan reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • NJ State Employees Deferred Compensation Plan sold 14,000 Verve Therapeutics shares in Q3 2025, an estimated $157K.
  • NJ State Employees Deferred Compensation Plan first reported a position in Verve Therapeutics in Q3 2022 and held it in 12 quarters.
  • NJ State Employees Deferred Compensation Plan's Verve Therapeutics position peaked at $481K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2025, filed 7 Nov 2025.